We report a case of a 74-year-old man with a metastatic anaplastic pancreatic carcinoma (APC). After an early tumour progression on first-line chemotherapy with cisplatin and gemcitabine, even though it was badly tolerated, he was treated with a combination of systemic modified FOLFIRI and high-intensity focused ultrasound (HIFU) on the pancreatic mass. A tumour showing partial response with a clinical benefit was obtained. HIFU was preferred to radiotherapy because of its shorter course and minimal side effects, in order to improve the patient's clinical conditions. The patient is currently on chemotherapy, asymptomatic with a good performance status. In referral centres, with specific expertise, HIFU could be safely and successfully combi...
Traditional oncological interventions have failed to improve survival for pancreatic cancer patients...
Pancreatic cancer is the fourth cause of mortality worldwide while liver cancer is the sixth most co...
Pancreatic ductal adenocarcinoma (PDAC) has a bleak prognosis, especially for the majority of patien...
Pancreatic cancer is under high mortality but has few effective treatment modalities. High-intensity...
Pancreatic cancer is under high mortality but has few effective treatment modalities. High-intensity...
To evaluate the safety and efficacy of high intensity focused ultrasound for palliation of inoperabl...
Abstract Objective: To observe the efficacy of high-intensity focused ultrasound (HIFU) in the treat...
High-intensity focused ultrasound (HIFU) is a novel advanced therapy for unresectable pancreatic can...
Introduction High-intensity focused ultrasound (HIFU) for pancreatic cancer is a growing therapeutic...
for the treatment of pancreatic cancer. Although we have made incremental progress in the treatment ...
This phase II trial was conducted to evaluate the safety and efficacy of concurrent gemcitabine and ...
Purpose This study aimed to compare the survival benefits between high-intensity focused ultrasound ...
Introduction Pancreatic cancer is with the poorest prognosis of all common cancers worldwide. Despit...
Zhouyu Ning, Jing Xie, Qiwen Chen, Chenyue Zhang, Litao Xu, Libin Song, Zhiqiang Meng Department of...
permits unrestricted use, distribution, and reproduction in any medium, provided the original work i...
Traditional oncological interventions have failed to improve survival for pancreatic cancer patients...
Pancreatic cancer is the fourth cause of mortality worldwide while liver cancer is the sixth most co...
Pancreatic ductal adenocarcinoma (PDAC) has a bleak prognosis, especially for the majority of patien...
Pancreatic cancer is under high mortality but has few effective treatment modalities. High-intensity...
Pancreatic cancer is under high mortality but has few effective treatment modalities. High-intensity...
To evaluate the safety and efficacy of high intensity focused ultrasound for palliation of inoperabl...
Abstract Objective: To observe the efficacy of high-intensity focused ultrasound (HIFU) in the treat...
High-intensity focused ultrasound (HIFU) is a novel advanced therapy for unresectable pancreatic can...
Introduction High-intensity focused ultrasound (HIFU) for pancreatic cancer is a growing therapeutic...
for the treatment of pancreatic cancer. Although we have made incremental progress in the treatment ...
This phase II trial was conducted to evaluate the safety and efficacy of concurrent gemcitabine and ...
Purpose This study aimed to compare the survival benefits between high-intensity focused ultrasound ...
Introduction Pancreatic cancer is with the poorest prognosis of all common cancers worldwide. Despit...
Zhouyu Ning, Jing Xie, Qiwen Chen, Chenyue Zhang, Litao Xu, Libin Song, Zhiqiang Meng Department of...
permits unrestricted use, distribution, and reproduction in any medium, provided the original work i...
Traditional oncological interventions have failed to improve survival for pancreatic cancer patients...
Pancreatic cancer is the fourth cause of mortality worldwide while liver cancer is the sixth most co...
Pancreatic ductal adenocarcinoma (PDAC) has a bleak prognosis, especially for the majority of patien...